Inactive Instrument

Analyst Reco. Innovate Biopharmaceuticals Inc Nasdaq

Equities

Citigroup Adjusts 9 Meters Biopharma Price Target to $0.75 From $1.70, Maintains Neutral Rating	23-05-18	MT
Truist Downgrades 9 Meters Biopharma to Hold From Buy	23-03-20	MT
Citigroup Initiates Coverage on 9 Meters Biopharma With Neutral Rating, $2.70 Price Target	23-02-13	MT
Oppenheimer Adjusts 9 Meters Biopharma Price Target to $51 From $5, Maintains Outperform Rating	22-11-02	MT
Oppenheimer Adjusts Price Target on 9 Meters Biopharma to $5 From $4, Maintains Outperform Rating	22-09-27	MT
Maxim Downgrades 9 Meters Biopharma to Hold From Buy	22-07-01	MT
Maxim Group Adjusts 9 Meters Biopharma Price Target to $1 From $2, Maintains Buy Rating	22-06-22	MT
Brookline Capital Markets Adjusts 9 Meters Biopharma Price Target to $4 From $6, Maintains Buy Rating	22-06-22	MT
BMO Capital Adjusts Price Target on 9 Meters Biopharma to $3 From $5, Keeps Outperform Rating	22-06-22	MT
Truist Securities Lowers 9 Meters Biopharma's Price Target to $2 From $5, Buy Rating Maintained	22-06-21	MT
Oppenheimer Adjusts 9 Meters Biopharma PT to $5 From $5.50, Maintains Outperform Rating	21-11-16	MT
9 METERS BIOPHARMA : BMO Capital Initiates 9 Meters Biopharma at Outperform Rating With $5 Price Target	21-07-08	MT
9 METERS BIOPHARMA : Citigroup Starts 9 Meters Biopharma at Buy With $3 Price Target	21-06-04	MT
9 METERS BIOPHARMA : Oppenheimer Adjusts 9 Meters Biopharma PT to $5.50 From $6, Maintains Outperform Rating	21-05-14	MT
9 METERS BIOPHARMA : Oppenheimer Starts 9 Meters Biopharma at Outperform With $6 Price Target	21-01-29	MT

No results for this search